Investors with an eye on the biotechnology sector may find Precigen, Inc. (NASDAQ: PGEN) an intriguing prospect, given its focus on innovative gene and cell therapies. With a robust market capitalization of $1.68 billion, this Germantown, Maryland-based biopharmaceutical company is making significant strides in the healthcare industry. Despite the recent dip in its stock price, Precigen presents a remarkable opportunity, particularly with a potential upside of 79.32% based on analyst target prices.

**Innovative Therapeutic Platforms**

Precigen is at the forefront of developing groundbreaking therapies using its proprietary technology platforms. The company’s AdenoVerse platform leverages a library of adenovectors for delivering…